^
    Back
    Association details:
    Biomarker:ER mutation
    Cancer:Breast Cancer
    Drug:Venclexta (venetoclax) (Bcl2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2-Positive Metastatic Breast Cancer

    Published date:
    12/05/2018
    Excerpt:
    Radiologic responses (40%) and clinical benefit (70%) were observed in 10 patients with plasma-detected ESR1 mutations.
    Secondary therapy:
    tamoxifen
    DOI:
    10.1158/2159-8290.CD-18-1151